| Literature DB >> 28835897 |
Rui Wu1, He Lv1, Wei Zhang1, Zhaoxia Wang1, Yuehuan Zuo1, Jing Liu1, Yun Yuan1.
Abstract
Charcot-Marie-Tooth 1A (CMT1A) caused by peripheral myelin protein 22 (PMP22) gene duplication is the most common form of hereditary polyneuropathy. Twenty-four genetically confirmed CMT1A patients with sural nerve biopsies were enrolled in this study. The clinical picture included a great variability of phenotype with mean onset age of 22.2 ± 14.5 years (1-55 years). Pathologically, we observed a severe reduction in myelinated fiber density showing three types of changes: pure onion bulb formation in 3 cases (12.5%), onion bulb formation with axonal sprouts in 10 cases (41.7%), and focally thickened myelin with onion bulb formation or/and axonal sprouts in 11 cases (45.8%). We observed no significant correlation between nerve fiber density and disease duration. There was no significant difference between the 3 pathological types in terms of clinical manifestations, nerve fiber density, and g-ratio. Our study indicates that there is marked variability in the age of onset of CMT1A, as well as significant pathological changes without deterioration with the development of the disease. Focally thickened myelin is another common morphological feature of demyelination.Entities:
Mesh:
Year: 2017 PMID: 28835897 PMCID: PMC5556987 DOI: 10.1155/2017/6481367
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Clinical features and nerve conduction studies (NCS) of the patients analyzed in this study.
| Patient number | Gender | Age of evaluation (years) | Age of onset (years) | Disease duration (years) | Strength of muscle | Pes cavus | Sensory loss | Areflexia | Muscle atrophy | Median nerve MCV (m/s) | Median nerve CMAP (mV) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper limb | Lower limb | Hand | Calf | ||||||||||
| 1 | F | 13 | 7 | 6 | 5 | 5 | Y | Y | Y | Y | N | 21.0 | 3.3 |
| 2 | M | 8 | 8 | 0.5 | 4 | 4 | N | N | Y | N | N | — | — |
| 3 | M | 27 | 26 | 1 | 5 | 2 | Y | Y | Y | N | N | — | — |
| 4 | M | 37 | 11 | 26 | 4 | 2 | Y | N | Y | N | N | 11.0 | 1.9 |
| 5 | M | 32 | 24 | 8 | 4 | 3 | N | Y | Y | Y | Y | 51.0 | 4.6 |
| 6 | M | 39 | 32 | 7 | 4 | 4 | N | Y | Y | Y | Y | — | — |
| 7 | F | 48 | 39 | 9 | 4 | 2 | N | N | Y | Y | Y | — | — |
| 8 | F | 45 | 25 | 20 | 5 | 4 | N | Y | Y | Y | Y | — | — |
| 9 | F | 9 | 5 | 3 | 5 | 4 | Y | Y | Y | N | N | 14.0 | 5 |
| 10 | F | 38 | 36 | 2 | 3 | 2 | Y | Y | N | Y | N | 14.0 | — |
| 11 | F | 28 | 13 | 15 | 4 | 4 | Y | Y | N | Y | N | 0 | 0 |
| 12 | F | 36 | 33 | 3 | 4 | 4 | Y | N | Y | Y | N | 20.0 | 1.3 |
| 13 | M | 8 | 1 | 7 | 4 | 4 | Y | N | Y | N | N | 30.0 | 5 |
| 14 | M | 33 | 23 | 10 | 3 | 3 | N | N | Y | Y | Y | — | — |
| 15 | M | 9 | 6 | 3 | 5 | 5 | Y | Y | Y | Y | Y | — | — |
| 16 | M | 59 | 55 | 4 | 5 | 4 | N | Y | Y | N | N | 22.0 | 2.4 |
| 17 | M | 21 | 2 | 18 | 4 | 1 | Y | Y | Y | N | Y | 22.1 | 7.9 |
| 18 | M | 31 | 30 | 1 | 5 | 5 | Y | N | Y | N | N | — | — |
| 19 | M | 42 | 39 | 3 | 4 | 4 | Y | Y | Y | Y | Y | 24.0 | — |
| 20 | M | 35 | 31 | 4 | 5 | 4 | Y | Y | Y | Y | Y | — | — |
| 21 | F | 36 | 32 | 4 | 5 | 3 | N | N | Y | N | N | 16.0 | 2.4 |
| 22 | F | 35 | 25 | 10 | 4 | 1 | N | Y | Y | Y | Y | 15.9 | 1 |
| 23 | M | 31 | 28 | 3 | 5 | 5 | N | Y | Y | N | N | 0 | 0 |
| 24 | F | 8 | 1.5 | 6 | 5 | 4 | N | N | Y | N | N | — | — |
Note. M: male; F: female; Y: yes; N: no; MCV: motor conduction velocity; CMAP: compound muscle action potential amplitude. Black bar means material defect.
Figure 1Composition of CMT1A patients with different ages of onset.
Comparison of clinical characteristics between three different pathological CMT1A subtypes.
| Subtype 1 | Subtype 2 | Subtype 3 | |
|---|---|---|---|
| Number of patients | 3 | 10 | 11 |
| Age at onset (years) | 19.7 ± 11.9 | 21.5 ± 12.1 | 23.5 ± 17.8 |
| Age at examination (years) | 25.0 ± 14.0 | 30.6 ± 12.7 | 29.7 ± 16.3 |
| Disease duration (years) | 5.3 ± 4.0 | 9.2 ± 8.4 | 6.0 ± 5.0 |
| Distal muscle weakness | |||
| Upper limbs | 4.7 ± 0.6 | 4.2 ± 0.6 | 4.5 ± 0.7 |
| Lower limbs | 3.7 ± 2.3 | 3.5 ± 0.8 | 3.4 ± 1.3 |
| Muscle atrophy | |||
| Hand | 2 (66.7%) | 7 (70%) | 4 (36.4%) |
| Calf | 2 (66.7%) | 4 (40%) | 4 (36.4%) |
| Sensory loss | 3 (100%) | 6 (60%) | 6 (54.5%) |
| Areflexia | 3 (100%) | 8 (80%) | 11 (100%) |
| Foot deformity | 1 (33.3%) | 5 (50%) | 7 (63.6%) |
Subtype 1: pure onion bulb formation; Subtype 2: onion bulb formation with axonal sprouts; Subtype 3: focally thickened myelin with onion bulb formation or/and axonal sprouts. P > 0.05.
Figure 2Sural nerve biopsy of a demyelination dominant CMT1A patient showing features of diffuse onion bulb lesions.
Figure 3Sural nerve biopsy of a mixed myelin-axonal damage CMT1A patient showing features of typical onion bulb lesions and regeneration clusters (black arrow).
Figure 4Sural nerve biopsy of a CMT1A patient showing features of focally thickened myelin (black arrow).